Mark Howard, MD
Sports Medicine · Monterey, CANPI 1255794731
Payments from drug & device makers
What this record shows
This record is dominated by education: $14,500 of the $18,637 with a category attached, or 77.8%. Smith+Nephew accounts for 72.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $16,206 and has fallen 97.8% since, to $359 in 2025.
Across 48 payments — averaging $388.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$13K
- Arthrex$3K
- Stryker$2K
- Zimmer Biomet$544
- Vericel Corporation$125
- Medical Device Business Services, Inc.$125
- plus $146 from 3 others
What the payments were for
- Grants$1251%
- Travel & lodging$2,15812%
- Food & beverage$1,85410%
- Education$14,50078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 2 | $13,431 |
| Arthrex | 21 | $2,539 |
| Stryker | 15 | $1,727 |
| Zimmer Biomet | 5 | $544 |
| Vericel Corporation | 1 | $125 |
| Medical Device Business Services, Inc. | 1 | $125 |
| Evolution Surgical, Inc | 1 | $111 |
| Bioventus LLC | 1 | $17 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,637 in reported general payments places this provider in the 75th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 30 | $981 |
| Meloxicam | 74 | $201 |
| Oxycodone Hcl | 39 | $147 |
| Ondansetron Hcl | 40 | $94 |
| Tramadol Hcl | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Monterey
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Michael FreehillStanford$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Seth ShermanStanford$1.1M
- Stephan YacoubianBurbank$1M
- Stephen Snydervan Nuys$922K
- Deryk JonesSan Carlos$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.